Don't invest unless you're prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more
|
|
|
|
|
|
The round has successfully passed its target and this is your final opportunity to back MetalloBio, the company creating broad-spectrum antibiotics to reduce infections and address $3.03 billion markets. As infectious bacteria become resistant to existing antibiotics, MetalloBio creates science-led solutions that appear not to trigger bacterial resistance readily, addressing a key gap in the market.
MetalloBio - founded in 2021, has already raised over £352k from 350 investors, reaching 146% of its target and is now overfunded with the round closing in few days.
Explore the campaign below and join the mission to address the safe conduct of cancer treatment, routine surgery, and general health - which all require effective antibiotics - before the round closes. 👇
|
|
🌏 MARKET OPPORTUNITY
-
Infection Markets: The complicated urinary tract infections market will be worth $3 billion by 2035.
-
Coatings Market: The antimicrobial catheter coatings market is projected to reach $2.56 billion by 2033.
-
Income Consolidation: Active (UK, Italy) and planned (US, EU, Japan, Australia) guaranteed minimum revenue schemes promise income consolidation for new antibiotics.
-
Broad Impact: Addressing a critical need where historically limited antibiotic drug designs affect routine surgery and general health.
|
|
-
Validated Science: Created over 45 new antibacterial compounds and efficacy against THE 7 major bacterial pathogens.
-
Superior Performance: Synthesised antibacterial materials that are up to 80,000 times more effective than marketed products.
-
Global Protection: Patents awarded in 24 countries, with underlying chemistry protected by trade secrets and industrial scale-up ready.
-
Award-Winning: MetalloBio won the Federation of Small Businesses Small Company of the Year award in 2023.
-
Grant Funding: Successfully received 5 prestigious UK government grants (Innovate UK), raising £1.269M in grants alongside £705k previous equity investment.
|
|
|
Funds will allow Metallobio to:
-
Clinical Studies: Establish safe dose levels and complete key toxicology testing.
-
Regulatory Strategy: Develop clinical trial strategy with regulatory experts.
-
Commercial Execution: Execute the coatings/materials licensing campaign.
-
IP Expansion: Submit new patent applications to add to the value of the company.
This is your final opportunity to support a business addressing one of the most critical gaps in the healthcare market.
|
|
|
|
|
Investing involves risks, including the risk of partial or entire loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Your investment is not covered by a deposit guarantee scheme or by an investor compensation and scheme. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future. Republic Europe does not make investment recommendations to you and any investment decision should be made on the basis of the full campaign. No communications from Republic Europe, through email or any other medium, should be construed as an investment recommendation.
|
|
|
This financial promotion and marketing communication has been approved by Seedrs Limited, authorised and regulated by the Financial Conduct Authority and Seedrs Europe Limited regulated by the Central Bank of Ireland both trading as Republic Europe, on 9 March 2026.
© Seedrs Limited 2026. All rights reserved. Republic Europe is a registered European Community trademark (No. 008771537), registered United Kingdom trademark (No. UK00908771537) and registered United States service mark (No. 85423072). Seedrs Europe Limited is a private company limited by shares registered in Ireland (No. 699574), with registered office at 42, Pearse Street, Dublin 2, D02 YX88, Ireland. Seedrs Limited is a limited company registered in England and Wales (No. 06848016), with registered office at Cubo Soho, Ilona Rose House, Manette Street, London W1D 4AL, United Kingdom, VAT No. GB 208 3065 32.
europe.republic.com is a website owned and operated by Seedrs Europe Limited and/or Seedrs Limited (each trading as Republic Europe).
This message and any attachments are confidential, and may be protected by legal privilege. Nothing in this message shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind, and nothing in this email constitutes such advice. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe or its affiliates, you should consult a professional adviser.
Don't want to receive any Featured Campaign Updates? Unsubscribe here. To manage your Republic Europe marketing communications please visit your preferences centre.
|
|
|
|
